$LH

The Lewin Group, a subsidiary of Optum (UnitedHealth Group), secured an $11.3M contract from CMS for long-term healthcare innovation support, signaling continued federal investment in healthcare modernization. This award is particularly relevant given the recent Executive Order on accelerating medical treatments for serious mental illness, which could drive further demand for such support services.

HR8260 is a procedural early-stage bill with zero funding authorization and no market-moving catalyst. No price action has been observed in LH ($260.86) or DGX ($193.96) related to this legislation. The bill has only been referred to committee; passage probability is low at this time.

The CARE Act of 2025 (S.3145) requires CMS to test a Medicare payment model for ground ambulance dispatches that do not result in transport, creating a new revenue stream for ambulance providers and ancillary services. While only introduced and referred to committee, the bipartisan sponsorship and House companion bill provide credible legislative momentum. Evolent Health ($EVH) and Labcorp ($LH) are positioned as indirect beneficiaries through care coordination platforms and diagnostic lab services, respectively. The bill has no explicit funding authorization — it mandates a model test, not direct appropriations.

HR 3037 (Access to Breast Cancer Diagnosis Act) is an early-stage bill eliminating patient cost-sharing for diagnostic breast exams. The bill benefits diagnostic imaging providers $DGX and $LH through higher utilization, while insurers face increased claims costs. Passage is uncertain at this procedural stage, but bipartisan cosponsorship and a companion Senate bill signal moderate legislative momentum.

HR6897 (Thyroid Disease CARE Act) authorizes $30M/year for five years for thyroid disease research and improved diagnostics. The bill is in early stage — referred to House Energy and Commerce Committee on December 18, 2025. Real market data shows diagnostic stocks trending negative over the past 30 days, with Labcorp down 1.53% and Abbott down 11.85%. Any impact is procedural and speculative at this stage.

S.3607 expands Medicare Part B to cover genetic counseling as a new provider category effective Jan 1, 2027, directly increasing the addressable patient population for genetic testing. This is a structural positive for Labcorp ($LH) and Quest Diagnostics ($DGX) through higher test volume, and for AMN Healthcare ($AMN) through increased demand for scarce genetic counselors. The bill is at early legislative stage (referred to Finance Committee) with companion bill HR6280 in the House.

The SCREENS for Cancer Act reauthorizes and expands national cancer screening programs for 2026-2030. This creates a structural volume tailwind for Labcorp ($LH) and Quest Diagnostics ($DGX) as the primary processors of screening lab work. Both stocks have been down over the past month on broader market weakness, not bill-specific news — the authorization provides a real federal program pipeline for incremental testing revenue once appropriations are secured.

The PrEP and PEP are Prevention Act (HR5127) mandates zero-cost coverage of HIV prevention drugs and associated lab monitoring across all US insurance programs. This early-stage bipartisan bill creates direct volume upside for Gilead ($GILD) on branded PrEP, Viatris ($VTRS) on generic PrEP, and Labcorp ($LH) on mandatory diagnostic services. Merck ($MRK) is excluded from the causal chain because its islatravir candidate is not FDA-approved and the bill only covers approved drugs.

The RESULTS Act (S.2761) proposes shifting Medicare Part B lab test payment rate data collection from CMS to an independent nonprofit, targeting the key revenue risk for $LH and $DGX under PAMA. The bill is early-stage (referred to committee) and faces a multi-year path, but its mechanism directly addresses a structural headwind that has driven ~10% cumulative Medicare rate cuts since 2018. Real market data shows a 5-day selloff in both tickers — $LH dropped from $270.68 to $263.99 and $DGX from $195.02 to $195.64 — creating an entry point for investors betting on legislative momentum for reimbursement stability.

S. 800 (Precision Brain Health Research Act of 2025) expands the VA's biomarker research mandate but authorizes zero new funding. The bill is reported out of committee and awaiting floor action. Labcorp ($LH at $262.63) and Quest Diagnostics ($DGX at $194.98) show no legislative catalyst in their recent price trends—both are down ~0.5-1.6% over the last 30 days. No near-term market impact.

HR3951 expands and extends the VA's contracted disability exam program through 2031, a procedural positive for outsourced exam providers like Labcorp ($LH). However, the bill authorizes no new funding and is early-stage (reported out of committee), with actual contract volume dependent on future VA appropriations. $LH has underperformed the market recently, closing at $264.19 on 2026-04-30 with a -0.98% 30-day return, indicating broader headwinds.

HR6178, introduced in November 2025 and referred to two committees, mandates no-cost lung cancer screenings and expanded tobacco cessation services under Medicaid, Medicare, and private insurance. This creates a direct revenue tailwind for diagnostic lab companies $LH and $DGX through increased test volume, and a pharmacy/PBM benefit for $CVS through mandated tobacco cessation drug coverage. Health insurers ($UNH, $HUM, $CNC, $MOH) face a neutral cost burden from the coverage mandate and prior authorization ban, with manageable MLR impact given the preventive nature of the service. The bill is early-stage with no appropriation attached.

The SUPPORT for Patients and Communities Reauthorization Act (P.L. 119-44) became law on December 1, 2025, extending federal substance use disorder and mental health funding through FY2030. This creates a structural tailwind for diagnostic testing (LH, DGX) and pharmaceutical distribution (CAH) via sustained grant programs, while also providing a positive policy backdrop for psychedelic therapy developers (CMPS, MNMD). Recent market data shows diagnostic stocks declining over the past 30 days, with LH at $261.79 (-1.88% 30d) and DGX at $193.52 (-1.26% 30d), suggesting the market has not yet priced in this long-term authorization catalyst.

HR1406 (Lung Cancer Screening and Prevention Act of 2025) would expand Medicare coverage to FDA-approved lung cancer screening tests beyond the current USPSTF-recommended set. The bill is in early committee stage with no authorized funding, limiting near-term market impact. GEHC, LH, and DGX are structural beneficiaries if passed, but passage is uncertain and distant.

HR7868, the 'Expanding Support for Living Donors Act of 2026,' is an early-stage bill authorizing up to $10,000 per donor for qualifying expenses in FY2027. Actual appropriations are required. The market reaction in diagnostic ($LH, $DGX) and device ($MDT, $SYK) stocks is currently driven by broader market trends — all four stocks are down 2-9% over the past 30 days — not by this bill's introduction. The legislative impact on revenue is negligible at this stage.

The 'Supporting Healthy Moms and Babies Act' (HR3762) is an early-stage bill that would mandate comprehensive maternity/newborn care coverage without cost-sharing under ACA plans. With 28 cosponsors, a companion bill in the Senate, and referral to three committees, legislative progress is early but has nominal bipartisan support. Insurers UNH and CI face increased medical costs, while diagnostic labs LH and DGX benefit from higher utilization. No dollar amount is authorized or appropriated.

The RESULTS Act (HR5269) is an early-stage bill aiming to stabilize Medicare reimbursement for clinical diagnostic lab tests by improving data accuracy. It has 77 cosponsors and a companion bill in the Senate but remains in committee with no near-term market impact. Real market data shows LH at $259 and DGX at $190.19, both down ~3% over 30 days, reflecting sector headwinds unrelated to this procedural legislation.

The ASAP Act (HR6130) mandates Medicare coverage for FDA-cleared blood-based dementia screening tests starting Jan 1, 2028. Labcorp ($LH) and Quest Diagnostics ($DGX) are the two largest independent lab operators with existing FDA-cleared blood-based dementia tests, making them primary beneficiaries of this new mandatory benefit category. The bill is in early legislative stages (referred to committee) with companion bill S3267 in the Senate, but the bipartisan sponsorship and 82 cosponsors indicate strong momentum for a mid-2027 passage timeline.

The CHOICE for Veterans Act of 2025 (HR3132) is awaiting floor action after being reported out of committee. This bill expands fee agreements for VA benefits claims, which is expected to improve claims efficiency and reimbursement rates for healthcare providers serving veterans. Companies like HCA Healthcare ($HCA), Universal Health Services ($UHS), Labcorp Holdings ($LH), and Quest Diagnostics ($DGX) are positioned to benefit from these operational improvements.

The Find It Early Act (S.1410), introduced in April 2025, would mandate no-cost-sharing coverage for advanced breast imaging for high-risk individuals and those with dense breast tissue. The bill is in early legislative stages (referred to committee) with no funding authorized. Real market data shows GEHC has fallen 14.88% in the last 7 days to $59.49, near its 52-week low, while UNH has surged 41.62% over 30 days to $370.74—moves driven by factors unrelated to this early-stage bill.

The Reducing Hereditary Cancer Act (HR4752) mandates Medicare coverage for germline mutation testing—a direct expansion of the addressable market for genetic diagnostics companies. The bill is in early committee stage (referred to Energy & Commerce and Ways & Means), with a Senate companion bill (S2760) also introduced. Real market data shows genetic testing/ diagnostics tickers have declined 0.09% to 5.12% in the past week, but this bill represents structural demand expansion independent of recent price action.

S. 339 authorizes Medicare coverage for FDA-approved multi-cancer early detection screening tests starting in 2028, creating a new government-reimbursed revenue stream for diagnostic companies. The bill is in early legislative stages (referred to committee since Jan 2025) with 68 cosponsors and an identical House companion that has advanced further. Pure-play liquid biopsy developers and reference laboratories with processing infrastructure are positioned to benefit.